Akeso shares take a hit despite surging sales of cancer drugs
The maker of oncology drugs posted higher half-year revenues but a widening net loss and share sales by its founders have dented investor confidence Key Takeaways: Drug sales rose 49%…
FAST NEWS: Simcere’s Covid drug trial shows promising results
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Thursday that newly published results of a Phase 2/3 clinical study for its innovative drug, Xiannuoxin, for the treatment of adult patients…
Recent Articles
RELATED ARTICLES
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK -
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
9939.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
